Marshall Edwards Receives FDA Approval of Investigational New Drug Application for Clinical Testing of Oncology Drug Candidate ME-344

Marshall Edwards, Inc.

, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has received approval from the U.S Food and Drug Administration (FDA) of its Investigational New Drug application for ME-344, the Company's lead mitochondrial inhibitor. The Company is now in the process of initiating a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors.